DataSheet7_miR-92a-3p Promoted EMT via Targeting LATS1 in Cervical Cancer Stem Cells.ZIP
miR-92a-3p (microRNA-92a-3p) has been reported to be dysregulated in several cancers, and as such, it is considered to be a cancer-related microRNA. However, the influence of miR-92a-3p on biological behaviors in cervical cancer (CC) still remains unclear. Quantitative real-time PCR was used to detect miR-92a-3p levels in CC stem cells. Here, Cell Counting Kit-8 (CCK8) assay, Transwell cell invasion assay and flow cytometry assay were used to characterize the effects that miR-92a-3p and large tumor suppressor l (LATS1) had on proliferation, invasion and cell cycle transition. The luciferase reporter gene assay was used to verify the targeting relationship between miR-92a-3p and LATS1. Western Blotting was used to investigate the related signaling pathways and proteins. Data from The Cancer Genome Atlas (TCGA) showed that miR-92a-3p was upregulated in CC tissues and closely associated with overall survival. miR-92a-3p promoted proliferation, invasion and cell cycle transition in CC stem cells. The luciferase reporter assay showed that miR-92a-3p bound to the 3′-untranslated region (3′-UTR) of the LATS1 promoter. LATS1 inhibited proliferation, invasion and cell cycle transition. Results measured by Western Blotting showed that LATS1 downregulated expressions of transcriptional co-activator with PDZ-binding motif (TAZ), vimentin and cyclin E, but upregulated the expression of E-cadherin. Re-expression of LATS1 partly reversed the effects of miR-92a-3p on proliferation, invasion and cell cycle transition, as well as on TAZ, E-cadherin, vimentin, and cyclin E. miR-92a-3p promoted the malignant behavior of CC stem cells by targeting LATS1, which regulated TAZ and E-cadherin.
History
References
- https://doi.org//10.1038/cgt.2016.10
- https://doi.org//10.1074/jbc.m117.801373
- https://doi.org//10.5582/bst.2015.01170
- https://doi.org//10.1016/j.biopha.2018.07.158
- https://doi.org//10.1016/j.tranon.2017.12.012
- https://doi.org//10.1186/s12967-019-1869-4
- https://doi.org//10.1038/nrc3458
- https://doi.org//10.18632/oncoscience.398
- https://doi.org//10.1016/j.cellsig.2016.08.004
- https://doi.org//10.1016/j.ydbio.2009.07.043
- https://doi.org//10.7754/Clin.Lab.2016.160610
- https://doi.org//10.3892/ijmm.2019.4258
- https://doi.org//10.1006/meth.2001.1262
- https://doi.org//10.3892/etm.2017.4586
- https://doi.org//10.1038/ncb3035
- https://doi.org//10.1016/j.canlet.2014.09.021
- https://doi.org//10.3892/ol.2019.10462
- https://doi.org//10.3322/caac.21551
- https://doi.org//10.3390/cancers10040094
- https://doi.org//10.3390/ijms20184406
- https://doi.org//10.3892/ol.2020.11443
- https://doi.org//10.1186/s12943-018-0829-6
- https://doi.org//10.1097/md.0000000000005642
- https://doi.org//10.1016/j.bbrc.2015.01.066